Oral pill aims to boost power of melanoma immunotherapy
NCT ID NCT05089370
Summary
This study is testing whether adding an oral drug called DEC-C to a standard immunotherapy (nivolumab) can make treatment more effective for people with advanced mucosal melanoma that cannot be removed by surgery. The goal is to see if this combination is safe and can better control the cancer by helping the patient's own immune system fight the tumor. The trial will involve a small group of adults with this specific type of melanoma.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Colorado Hospital
Aurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.